Sable Bio Secures £1.5M in Pre-Seed Funding to Enhance Drug Safety Testing

Sable Bio Secures £1.5M in Pre-Seed Funding to Enhance Drug Safety Testing

Sable Bio, a London-based B2B biotech startup, has successfully completed a pre-seed funding round, raising £1.5 million. This investment, led by Episode 1 Ventures and supported by Seedcamp, marks a significant step forward for the company established in 2023.

The startup, founded by a team of experts in AI-driven drug discovery, is focused on improving drug safety assessment processes through innovative technology. Sable Bio employs artificial intelligence to analyze extensive biomedical data sets, providing insights into the potential toxicity of new medicines. Co-founder Josh Almond-Thynne expressed optimism about the funding, stating, “This investment will enable Sable Bio to redefine drug safety assessment and generate actionable biomedical insights.”

A key aspect of Sable Bio’s approach is the utilization of large language models (LLMs), which facilitate the extraction of valuable data from scientific literature. Adam Shuaib, a partner at Episode 1, emphasized the significance of this technological advancement, noting its potential to streamline clinical trials and reduce associated costs.

Tom Wilson, a partner at Seedcamp, highlighted the importance of addressing delays in drug development caused by toxicity-related issues. “Sable is well-positioned to address this challenge by providing timely access to critical data,” Wilson remarked.

The funding will support Sable Bio in strengthening its core technological infrastructure and forging partnerships with biotech, pharma, and healthtech companies, as well as academic institutions. With a focus on expanding its team, the company aims to accelerate the development of safer drugs, ultimately benefiting patients.

Sable Bio’s commitment to leveraging AI and advanced data analysis techniques underscores its dedication to improving drug safety testing processes.

About Sable Bio:

Sable Bio is a London-based B2B biotech startup focused on enhancing drug safety testing through AI-driven approaches. Founded in 2023, the company aims to provide valuable insights into the toxicity of potential medicines, ultimately improving patient outcomes.

About Episode 1 Ventures:

Episode 1 Ventures is an early-stage fund that invests in B2B software companies across the UK. With a focus on supporting innovative startups, Episode 1 Ventures aims to drive technological advancements and foster growth within the industry.

About Seedcamp:

Seedcamp is a leading seed fund in Europe, backing founders who are addressing global challenges through technology-driven solutions. With a diverse portfolio of startups, Seedcamp plays a vital role in shaping the future of innovation.

Leave a Reply

Your email address will not be published. Required fields are marked *